Compare Stocks: GERN, ALKS, AMLX, and IDYA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$41.74 +1.3%	$45.02	$27.00 ▼ $55.67	$6.95B	0.32	2.14 million shs	11,328 shs
AMLX Amylyx Pharmaceuticals	$26.84 +1.9%	$30.91	$10.83 ▼ $41.14	$2.95B	-0.1	1.64 million shs	255 shs
GERN Geron	$1.19 +1.3%	$1.38	$1.04 ▼ $2.01	$760.05M	0.61	13.61 million shs	6,084 shs
IDYA IDEAYA Biosciences	$33.56 +2.2%	$37.95	$26.81 ▼ $42.68	$2.91B	-0.04	1.02 million shs	452 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	0.00%	+1.50%	-5.00%	-20.30%	+36.22%
AMLX Amylyx Pharmaceuticals	0.00%	-6.40%	-18.73%	+50.95%	+76.19%
GERN Geron	0.00%	-4.49%	-10.00%	-18.75%	-2.50%
IDYA IDEAYA Biosciences	0.00%	-9.03%	-14.48%	-7.33%	+12.27%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$41.74 +1.3%	$45.02	$27.00 ▼ $55.67	$6.95B	0.32	2.14 million shs	11,328 shs
AMLX Amylyx Pharmaceuticals	$26.84 +1.9%	$30.91	$10.83 ▼ $41.14	$2.95B	-0.1	1.64 million shs	255 shs
GERN Geron	$1.19 +1.3%	$1.38	$1.04 ▼ $2.01	$760.05M	0.61	13.61 million shs	6,084 shs
IDYA IDEAYA Biosciences	$33.56 +2.2%	$37.95	$26.81 ▼ $42.68	$2.91B	-0.04	1.02 million shs	452 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	0.00%	+1.50%	-5.00%	-20.30%	+36.22%
AMLX Amylyx Pharmaceuticals	0.00%	-6.40%	-18.73%	+50.95%	+76.19%
GERN Geron	0.00%	-4.49%	-10.00%	-18.75%	-2.50%
IDYA IDEAYA Biosciences	0.00%	-9.03%	-14.48%	-7.33%	+12.27%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALKS Alkermes	2.68	Moderate Buy	$54.47	30.51% Upside
AMLX Amylyx Pharmaceuticals	3.00	Buy	$40.71	51.72% Upside
GERN Geron	2.20	Hold	$4.00	237.55% Upside
IDYA IDEAYA Biosciences	2.82	Moderate Buy	$52.36	56.01% Upside

Current Analyst Ratings Breakdown

Latest GERN, ALKS, AMLX, and IDYA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/19/2026	IDYA IDEAYA Biosciences	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
10/16/2026	IDYA IDEAYA Biosciences	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform
10/16/2026	ALKS Alkermes	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$55.00
10/15/2026	IDYA IDEAYA Biosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	AMLX Amylyx Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$32.00 ➝ $39.00
10/14/2026	IDYA IDEAYA Biosciences	Stifel Nicolaus Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$48.00
9/24/2026	ALKS Alkermes	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Neutral	$50.00
9/24/2026	ALKS Alkermes	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Hold	$50.00
9/22/2026	IDYA IDEAYA Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight
9/22/2026	ALKS Alkermes	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$56.00
9/22/2026	ALKS Alkermes	Robert W. Baird Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$58.00 ➝ $61.00

(Data available from 10/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALKS Alkermes	$1.67B	4.20	$1.70 per share	24.62	$11.02 per share	3.79
AMLX Amylyx Pharmaceuticals	N/A	N/A	N/A	N/A	$2.78 per share	N/A
GERN Geron	$204.56M	3.72	N/A	N/A	$0.35 per share	3.39
IDYA IDEAYA Biosciences	$218.71M	13.48	N/A	N/A	$11.67 per share	2.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALKS Alkermes	$241.66M	$0.38	108.96	173.90	N/A	3.96%	4.15%	2.19%	10/28/2026 (Estimated)
AMLX Amylyx Pharmaceuticals	-$144.74M	-$1.43	N/A	N/A	N/A	N/A	-52.92%	-48.53%	11/5/2026 (Estimated)
GERN Geron	-$83.50M	-$0.11	N/A	19.75	N/A	-34.17%	-24.48%	-10.30%	11/4/2026 (Estimated)
IDYA IDEAYA Biosciences	-$113.70M	-$1.94	N/A	N/A	N/A	-75.93%	-16.73%	-15.34%	11/9/2026 (Estimated)

Latest GERN, ALKS, AMLX, and IDYA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	IDYA IDEAYA Biosciences	-$1.18	N/A	N/A	N/A	$7.12 million	N/A
11/5/2026	Q3 2026	AMLX Amylyx Pharmaceuticals	-$0.3805	N/A	N/A	N/A	$0.06 million	N/A
11/4/2026	Q3 2026	GERN Geron	-$0.01	N/A	N/A	N/A	$60.70 million	N/A
10/28/2026	Q3 2026	ALKS Alkermes	-$0.0809	N/A	N/A	N/A	$463.64 million	N/A
8/6/2026	Q2 2026	AMLX Amylyx Pharmaceuticals	-$0.3609	-$0.39	-$0.0291	-$0.39	N/A	N/A
8/5/2026	Q2 2026	GERN Geron	-$0.0089	-$0.02	-$0.0111	-$0.02	$55.30 million	$57.48 million
8/4/2026	Q2 2026	IDYA IDEAYA Biosciences	-$1.06	-$1.22	-$0.16	-$1.22	$8.02 million	$8.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
AMLX Amylyx Pharmaceuticals	$1.02	3.79%	N/A	N/A	N/A
GERN Geron	N/A	N/A	N/A	N/A	N/A
IDYA IDEAYA Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALKS Alkermes	0.82	2.30	1.85
AMLX Amylyx Pharmaceuticals	N/A	12.12	12.12
GERN Geron	0.55	6.91	5.16
IDYA IDEAYA Biosciences	N/A	10.45	10.45

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALKS Alkermes	95.21%
AMLX Amylyx Pharmaceuticals	95.84%
GERN Geron	73.71%
IDYA IDEAYA Biosciences	98.29%

Insider Ownership

Company	Insider Ownership
ALKS Alkermes	4.59%
AMLX Amylyx Pharmaceuticals	10.90%
GERN Geron	1.71%
IDYA IDEAYA Biosciences	4.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALKS Alkermes	2,050	167.76 million	160.06 million	Optionable
AMLX Amylyx Pharmaceuticals	136	111.42 million	99.28 million	Optionable
GERN Geron	258	642.47 million	631.49 million	Optionable
IDYA IDEAYA Biosciences	145	87.86 million	83.73 million	Optionable

GERN, ALKS, AMLX, and IDYA Headlines

Recent News About These Companies

Ideaya Biosciences (IDYA) Reiterated at Market Outperform by Citizens - Ph2 OptiMUM-01 Results Coming Up

3 hours ago | streetinsider.com

IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma

3 hours ago | prnewswire.com

William Blair sets USD 51.00 target for IDEAYA Biosciences stock

October 17 at 8:11 PM | ad-hoc-news.deA

William Blair initiates coverage of IDEAYA Biosciences with outperform

October 16 at 10:17 PM | msn.com

William Blair Initiates Coverage on IDEAYA Biosciences With Outperform Rating

October 16 at 12:15 PM | marketscreener.comM

Stifel Nicolaus Initiates Coverage on IDEAYA Biosciences (NASDAQ:IDYA)

October 16 at 1:36 AM | americanbankingnews.com

Stifel sets USD 48.00 target for IDEAYA Biosciences stock

October 15, 2026 | ad-hoc-news.deA

Stifel initiates coverage of IDEAYA Biosciences with buy

October 14, 2026 | msn.com

IDEAYA resumed at Buy at Stifel on combo treatment for uveal melanoma

October 14, 2026 | seekingalpha.com

IDEAYA Biosciences (NASDAQ:IDYA) Now Covered by Analysts at Stifel Nicolaus

October 14, 2026 | marketbeat.com

IDEAYA Biosciences (NASDAQ:IDYA) CEO Sells $985,304.58 in Stock

October 11, 2026 | defenseworld.netD

Insider Selling: IDEAYA Biosciences (NASDAQ:IDYA) CEO Sells 26,338 Shares of Stock

October 9, 2026 | insidertrades.com

IDEAYA Biosciences (NASDAQ:IDYA) Stock: Insider Yujiro Hata Sells 26,338 Shares

October 8, 2026 | marketbeat.com

IDEAYA Biosciences (NASDAQ:IDYA) vs. Sangamo Therapeutics (NASDAQ:SGMO) Head to Head Review

October 8, 2026 | americanbankingnews.com

IDEAYA Biosciences, Inc. $IDYA Holdings Lifted by Congress Asset Management Co.

October 8, 2026 | marketbeat.com

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Rating of "Moderate Buy" from Analysts

October 4, 2026 | marketbeat.com

IDEAYA Biosciences stock reports Q2 revenue growth despite loss

October 1, 2026 | ad-hoc-news.deA

IDEAYA Biosciences (NASDAQ:IDYA) Shares Climb 4.8% - Here's Why

September 28, 2026 | marketbeat.com

IDEAYA promotes Michael White to R&D president

September 28, 2026 | grafa.comG

IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development

September 28, 2026 | prnewswire.com

Can IDEAYA Biosciences (IDYA) Turn Uncharted Oncology Territory Into Commercial Gold?

September 25, 2026 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GERN, ALKS, AMLX, and IDYA Company Descriptions

Alkermes NASDAQ:ALKS

$41.74 +0.52 (+1.25%)

As of 09:33 AM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Amylyx Pharmaceuticals NASDAQ:AMLX

$26.84 +0.50 (+1.88%)

As of 09:32 AM Eastern

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

Geron NASDAQ:GERN

$1.18 +0.02 (+1.28%)

As of 09:33 AM Eastern

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

IDEAYA Biosciences NASDAQ:IDYA

$33.56 +0.71 (+2.16%)

As of 09:33 AM Eastern

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GERN, ALKS, AMLX, and IDYA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GERN, ALKS, AMLX, and IDYA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GERN, ALKS, AMLX, and IDYA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GERN, ALKS, AMLX, and IDYA Company Descriptions

Alkermes NASDAQ:ALKS

Amylyx Pharmaceuticals NASDAQ:AMLX

Geron NASDAQ:GERN

IDEAYA Biosciences NASDAQ:IDYA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GERN, ALKS, AMLX, and IDYA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GERN, ALKS, AMLX, and IDYA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GERN, ALKS, AMLX, and IDYA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GERN, ALKS, AMLX, and IDYA Company Descriptions

Alkermes NASDAQ:ALKS

Amylyx Pharmaceuticals NASDAQ:AMLX

Geron NASDAQ:GERN

IDEAYA Biosciences NASDAQ:IDYA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools